LX102 subretinal injection

GENETIC2 trials

Sponsors

Innostellar Biotherapeutics Co.,Ltd

Conditions

Neovascular Age-Related Macular Degeneration

Phase 1

LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

Active, not recruitingNCT06198413

Innostellar Biotherapeutics Co.,LtdNeovascular Age-Related Macular Degeneration

Start: 2023-02-27End: 2029-01-31Updated: 2025-07-01

Phase 2

Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)

Active, not recruitingNCT06196840

Innostellar Biotherapeutics Co.,LtdNeovascular Age-Related Macular Degeneration

Start: 2024-01-24End: 2029-10-01Target: 50Updated: 2026-03-06

Related Papers

Subretinal rAAV2-based VEGF-Trap gene therapy for neovascular age-related macular degeneration: Preclinical assessment and phase 1 trial results.

2026-06-12